Aevi Genomic Medicine — Investor Presentation (August 2019)
36 slides from Aevi Genomic Medicine's investor presentation, Aug 7, 2019
Slide 1: Company Overview Summer 2019
© 2019, Aevi Genomic Medicine Company Overview Summer 2019
Slide 2: Forward-Looking Statement
© 2019, Aevi Genomic Medicine Confidential | 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operat
Slide 3: Executive Summary
© 2019, Aevi Genomic Medicine Confidential | 3 Executive Summary • Driven by a commitment to patients with pediatric onset life - altering diseases, the company's research and development efforts include working with the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP)
Slide 4: Current Pipeline
© 2019, Aevi Genomic Medicine Confidential | 4 Compound Indication Preclinical Phase 1 Phase 2 Status Project Daytona GLA/Lymphatic Malformations Project Jackson Rare auto - inflammatory diseases AEVI - 004 Preclinical POC with NIH in epilepsy AEVI - 002* (anti - LIGHT mAb) Severe Pediatric Onset Cr
Slide 5: Management Team
© 2019, Aevi Genomic Medicine Confidential | 5 Michael F. Cola Chief Executive Officer Garry A. Neil, MD Chief Scientific Officer Sol J. Barer, PhD Chairman Management Team
Slide 6: Project Daytona
© 2019, Aevi Genomic Medicine Confidential | 6 Project Daytona
Slide 7: Executive Summary: Project Daytona
© 2019, Aevi Genomic Medicine Confidential | 7 Executive Summary: Project Daytona • OSI - 027 is a high potency second generation oral dual inhibitor of mTORC1 and mTORC2 which is Phase 2 ready in a serious Rare and Orphan disease with no approved therapies – OSI - 027 has a clear mechanism of actio
Slide 8: Deal Terms
© 2019, Aevi Genomic Medicine Confidential | 8 Deal Terms • Summary Terms – Worldwide License for all indications – $500,000 Upfront Licensing Fee – Additional Payments Based Upon Achieving Development and Regulatory Milestones – Tiered, High Single - Digit to Low Double - Digit Aggregate Royalties
Slide 9: The Lymphatic System
© 2019, Aevi Genomic Medicine Confidential | 9 The Lymphatic System • Lymph begins as fluid that has diffused through the very thin walls of capillaries into the space between cells. In a normal person this is about 3 liters per day • Lymph vessels, located throughout the body, are larger than capil
Slide 10: Lymphatic Malformations are a Family of Potentially Life-Threatening Congenital Diseases
© 2019, Aevi Genomic Medicine Confidential | 10 Lymphatic Malformations are a Family of Potentially Life - Threatening Congenital Diseases of the Lymphatic System • Presentation from birth to 2 years of age • Orphan disease(s) with pleiomorphic presentation • All caused by mutations (mostly in PI3K/
Slide 11: Disease Mechanism: Somatic Mutations in Tyrosine Kinase Signaling
© 2019, Aevi Genomic Medicine Confidential | 11 Disease Mechanism: Somatic Mutations in Tyrosine Kinase Signaling Lead to Abnormal Proliferation of Endothelial Cells and Disruption of Lymph Flow • Various mutations in tyrosine kinase receptors and downstream signaling components have been identified
Slide 12: Lymphatic Malformations are Rare and Potentially Life-Threatening Diseases
© 2019, Aevi Genomic Medicine Confidential | 12 Lymphatic Malformations are Rare and Potentially Life - Threatening Diseases • KLA: Kaposiform Lymphangiomatosis, aggressive presentation of lymphatic anomaly with coagulopathy and focal areas of spindle cells – US prevalence: approximately 1,000 1 – O
Slide 13: Off-Label Use of Sirolimus Shows POC in Lymphatic Malformations
© 2019, Aevi Genomic Medicine Confidential | 13 Off - Label Use of mTORC1 Inhibitor Sirolimus Shows POC in Open - Label Clinical Trial in Lymphatic Malformations 1. Adams et al. (2016) Pediatrics . 137(2):e20153257. • The study enrolled patients with different subtypes of lymphatic malformations not
Slide 14: Physician views on sirolimus limitations
© 2019, Aevi Genomic Medicine Confidential | 14 • Physicians expressed interest in better validation of the use of sirolimus and desire for therapeutic options with greater validation • Evidence supporting use of sirolimus in vascular malformations is limited to case reports and one academic clinica
Slide 15: OSI-027 Overview
© 2019, Aevi Genomic Medicine Confidential | 15 OSI - 027 Overview • High potency second generation oral dual inhibitor of mTORC1 and mTORC2 – Dual inhibition of mTORC1 and mTORC2 could lead to improved efficacy and tolerability • Phase 2 ready – Comprehensive pre - clinical toxicology package (up t
Slide 16: OSI-027 Potential Advantages over First Generation mTOR Inhibitors
© 2019, Aevi Genomic Medicine Confidential | 16 OSI - 027 has Several Potential Advantages over First Generation mTOR Inhibitors • OSI - 027 would be the first approved therapeutic product indicated for treatment of lymphatic malformations – Lack of FDA approval discourages off - label use and reimb
Slide 17: Long Term Efficacy and Safety are Critical For Life-long Therapy
© 2019, Aevi Genomic Medicine Confidential | 17 Long Term Efficacy and Safety are Critical For Life - long Therapy • PIK3CA inhibitors – Most proximal in pathway, very important in glucose regulation; inhibition results in tolerability issues: diabetes, pancreatitis, diarrhea • AKT inhibitors – Prox
Slide 18: Anticipated Rapid Orphan Drug Development Path to Approval
© 2019, Aevi Genomic Medicine Confidential | 18 Anticipated Rapid Orphan Drug Development Path to Approval Estimated Cost to POC $15 - 20M, Initial Data 2H 2020 • PK /PD Proof - of - Concept Trial Design: – To establish efficacy, safety, biomarkers and dose – Duration: 4 weeks, long - term safety st
Slide 19: Lymphatic Malformations Market Opportunity
© 2019, Aevi Genomic Medicine Confidential | 19 Lymphatic Malformations Market Opportunity Estimated Peak Annual Sales for US market: $450 - 900 Million • Lymphatic malformations including GLA, GSD, and KLA, present an attractive potential market opportunity: – Estimated Prevalence: 30,000 - 60,000
Slide 20: Project Jackson
© 2019, Aevi Genomic Medicine Confidential | 20 Project Jackson
Slide 21: Executive Summary: Project Jackson
© 2019, Aevi Genomic Medicine Confidential | 21 Executive Summary: Project Jackson • MEDI2338 is a high affinity fully human monoclonal antibody against IL - 18, Phase 2 ready for Rare and Orphan IL - 18 driven immunologic diseases with significant unmet need – Initially developed for COPD; halted f
Slide 22: Deal Terms
© 2019, Aevi Genomic Medicine Confidential | 22 Deal Terms • Summary Terms – The Right to Option a Worldwide License for all indications – Mid - Single Digit Millions in Cash and Equity Upon Exercise of the Option – Up to $162 Million Upon Achieving Approval and Sales - Related Milestones – Tiered L
Slide 23: IL-18 is Key to the Autoinflammatory Cascade
© 2019, Aevi Genomic Medicine Confidential | 23 IL - 18 is Key to the Autoinflammatory Cascade • IL - 18 is a pro - inflammatory cytokine produced by macrophages and osteoblasts • IL - 18 induces severe inflammatory reaction by stimulating production and release of interferon - gamma (IFN ࢽ ) in imm
Slide 24: Target IL-18 Driven Autoinflammatory Orphan Diseases
© 2019, Aevi Genomic Medicine Confidential | 24 Target IL - 18 Driven Autoinflammatory Orphan Diseases 1. Kudela et al. (2019) BMC Rheumatol. 3:4. 2. de Jager et al. (2008) Ann Rheum Dis. 67(2):280 3. Park et al. (2006) Rheumatology 45(5):545 - 8 4. Shinoda et al. (2006) J Gastroenterol Hepatol . 21
Slide 25: Adult Onset Still's Disease (AOSD)
© 2019, Aevi Genomic Medicine Confidential | 25 Adult Onset Still’s Disease (AOSD): Adult form of sJIA • Rare and orphan disease 1 : – US prevalence: 3,500 - 7,000 – EU5 prevalence: 3,400 - 6,900 – Japan prevalence: 1,400 - 2,700 • Fever, Rash, Pharyngitis, Arthritis, Liver disease, Increased ferrit
Slide 26: IL-18 Levels Elevated in sJIA and AOSD Patients
© 2019, Aevi Genomic Medicine Confidential | 26 IL - 18 Levels Elevated in sJIA and AOSD Patients • Serum IL - 18 levels were significantly elevated in sJIA and AOSD patients (up to 1,000 - fold higher) compared to the healthy control group • There is a significant association of serum IL - 18 level
Slide 27: Clinical POC Data in AOSD Using an IL-18 Binding Protein
© 2019, Aevi Genomic Medicine Confidential | 27 Clinical POC Data in AOSD Using an IL - 18 Binding Protein (IL - 18bp) • An open - label clinical study was recently completed by AB2 Bio for recombinant IL - 18 binding protein (IL - 18bp) in AOSD (n=23) 1 – Treatment of AOSD patients with a recombina
Slide 28: Project Jackson: IL-18 mAb
© 2019, Aevi Genomic Medicine Confidential | 28 Project Jackson: IL - 18 mAb • A high affinity fully human monoclonal antibody against IL - 18, for Rare and Orphan IL - 18 driven immunologic diseases with significant unmet need – High affinity (KD = 60 - 70 pM ), neutralizing monoclonal antibody (α
Slide 29: Anticipate Rapid Orphan Drug Development Path to Approval
© 2019, Aevi Genomic Medicine Confidential | 29 Anticipate Rapid Orphan Drug Development Path to Approval Estimated Cost to POC $15 - 20M, initial data 2H 2020 • Dose - Ranging Proof - of - Concept Trial Design: – To establish efficacy, safety, biomarkers and dose – Duration: 13 weeks, long - term s
Slide 30: AOSD and sJIA Present an Estimated $700-850M Market Opportunity
© 2019, Aevi Genomic Medicine Confidential | 30 AOSD and sJIA Present an Estimated $700 - 850M Market Opportunity • Significant upside potential in additional IL - 18 - opathies ClearView Healthcare Partners Analysis, May 2017 AOSD sJIA US prevalence 3,500 - 7,000 4,300 - 6,500 EU5 prevalence 3,400
Slide 31: Executive Summary
© 2019, Aevi Genomic Medicine Confidential | 31 Executive Summary • Driven by a commitment to patients with pediatric onset life - altering diseases, the company's research and development efforts include working with the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP
Slide 32: Appendix
© 2019, Aevi Genomic Medicine Confidential | 32 Appendix
Slide 33: Systemic Juvenile Idiopathic Arthritis (sJIA)
© 2019, Aevi Genomic Medicine Confidential | 33 Systemic Juvenile Idiopathic Arthritis ( sJIA ) • Rare childhood onset disease 1 – US prevalence: 4,300 - 6,500 – EU5 prevalence: 3,300 - 5,000 – Japan prevalence: 1,000 - 1,500 • Intermittent fever, rash and arthritis; often splenomegaly, lymph nodes
Slide 34: Zebrafish Model of Lymphatic Malformations
© 2019, Aevi Genomic Medicine Confidential | 34 Zebrafish Model of Lymphatic Malformations Li et al. (2018) Hum Mol Genet. 27(18):3233 - 3245. • Inhibiting ephb4a mRNA processing by morpholino injection results in: – mTOR activation – Expansion of the caudal vessel plexus – Aberrant vessel branching
Slide 35: Current Competitive Landscape for sJIA
© 2019, Aevi Genomic Medicine Confidential | 35 Current Competitive Landscape for sJIA • Patients are currently treated with steroids, immunosuppressants, and biologics (anti IL - 1 and anti IL - 6) – 15 - 30% of patients do not adequately respond to currently available therapies 1,2 – Non - respond
Slide 36: Current Competitive Landscape for AOSD
© 2019, Aevi Genomic Medicine Confidential | 36 Current Competitive Landscape for AOSD AOSD will be Our Initial Focus • AOSD patients are currently treated with steroids and immunosuppressants in the US, and biologics targeting IL - 1 in the EU – 15 - 30% of patients do not adequately respond to cur
Aevi Genomic Medicine — Investor Presentation (August 2019) on 6ix